141 related articles for article (PubMed ID: 37100681)
1. Remdesivir plus dexamethasone is associated to improvement in the clinical outcome of COVID-19 hospitalized patients regardless of their vaccination status.
Bernal E; García-Villalba E; Pons E; Hernández MD; Báguena C; Puche G; Carter P; Martinez M; Alcaraz A; Tomás C; Muñoz A; Vicente MR; Nuñez ML; Sancho N; Villalba MC; Cano A; Minguela A
Med Clin (Barc); 2023 Aug; 161(4):139-146. PubMed ID: 37100681
[TBL] [Abstract][Full Text] [Related]
2. Remdesivir in combination with dexamethasone for patients hospitalized with COVID-19: A retrospective multicenter study.
Gressens SB; Esnault V; De Castro N; Sellier P; Sene D; Chantelot L; Hervier B; Delaugerre C; Chevret S; Molina JM;
PLoS One; 2022; 17(2):e0262564. PubMed ID: 35176057
[TBL] [Abstract][Full Text] [Related]
3. Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19.
Ohl ME; Miller DR; Lund BC; Kobayashi T; Richardson Miell K; Beck BF; Alexander B; Crothers K; Vaughan Sarrazin MS
JAMA Netw Open; 2021 Jul; 4(7):e2114741. PubMed ID: 34264329
[TBL] [Abstract][Full Text] [Related]
4. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.
Ader F; Bouscambert-Duchamp M; Hites M; Peiffer-Smadja N; Poissy J; Belhadi D; Diallo A; Lê MP; Peytavin G; Staub T; Greil R; Guedj J; Paiva JA; Costagliola D; Yazdanpanah Y; Burdet C; Mentré F;
Lancet Infect Dis; 2022 Feb; 22(2):209-221. PubMed ID: 34534511
[TBL] [Abstract][Full Text] [Related]
5. Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide Population-Based Cohort Study.
Benfield T; Bodilsen J; Brieghel C; Harboe ZB; Helleberg M; Holm C; Israelsen SB; Jensen J; Jensen TØ; Johansen IS; Johnsen S; Lindegaard B; Lundgren J; Meyer CN; Mohey R; Pedersen LM; Nielsen H; Nielsen SL; Obel N; Omland LH; Podlekareva D; Poulsen BK; Ravn P; Sandholdt H; Starling J; Storgaard M; Søborg C; Søgaard OS; Tranborg T; Wiese L; Christensen HR
Clin Infect Dis; 2021 Dec; 73(11):2031-2036. PubMed ID: 34111274
[TBL] [Abstract][Full Text] [Related]
6. Remdesivir Plus Dexamethasone Versus Dexamethasone Alone for the Treatment of Coronavirus Disease 2019 (COVID-19) Patients Requiring Supplemental O2 Therapy: A Prospective Controlled Nonrandomized Study.
Marrone A; Nevola R; Sellitto A; Cozzolino D; Romano C; Cuomo G; Aprea C; Schwartzbaum MXP; Ricozzi C; Imbriani S; Rinaldi L; Gjeloshi K; Padula A; Ranieri R; Ruosi C; Meo LA; Abitabile M; Cinone F; Carusone C; Adinolfi LE
Clin Infect Dis; 2022 Aug; 75(1):e403-e409. PubMed ID: 35084022
[TBL] [Abstract][Full Text] [Related]
7. Remdesivir for the Treatment of Severe COVID-19: A Community Hospital's Experience.
Lee S; Santarelli A; Caine K; Schritter S; Dietrich T; Ashurst J
J Am Osteopath Assoc; 2020 Dec; 120(12):926-933. PubMed ID: 33136164
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19.
Garibaldi BT; Wang K; Robinson ML; Zeger SL; Bandeen-Roche K; Wang MC; Alexander GC; Gupta A; Bollinger R; Xu Y
JAMA Netw Open; 2021 Mar; 4(3):e213071. PubMed ID: 33760094
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors for poor outcomes in patients with severe COVID-19 treated with remdesivir plus dexamethasone in Taiwan.
Lai YH; Lee YC; Chen IR; Lin SN; Chang YL; Lu CC; Wu PF; Lin YT
J Microbiol Immunol Infect; 2023 Dec; 56(6):1207-1213. PubMed ID: 37696685
[TBL] [Abstract][Full Text] [Related]
10. Treatment effect modifiers in hospitalised patients with COVID-19 receiving remdesivir and dexamethasone.
Leding C; Bodilsen J; Brieghel C; Harboe ZB; Helleberg M; Holm C; Israelsen SB; Jensen J; Jensen TØ; Johansen IS; Johnsen S; Kirk O; Lindegaard B; Meyer CN; Mohey R; Pedersen L; Nielsen H; Nielsen SL; Omland LH; Podlekareva D; Ravn P; Starling J; Storgaard M; Søborg C; Søgaard OS; Tranborg T; Wiese L; Worm SHW; Christensen HR; Benfield T
Infect Dis (Lond); 2023 May; 55(5):351-360. PubMed ID: 36905638
[TBL] [Abstract][Full Text] [Related]
11. Survival benefit of remdesivir in hospitalized COVID-19 patients with high SARS-CoV-2 viral loads and low-grade systemic inflammation.
Padilla S; Polotskaya K; Fernández M; Gonzalo-Jiménez N; de la Rica A; García JA; García-Abellán J; Mascarell P; Gutiérrez F; Masiá M
J Antimicrob Chemother; 2022 Jul; 77(8):2257-2264. PubMed ID: 35534369
[TBL] [Abstract][Full Text] [Related]
12. Remdesivir plus Dexamethasone in COVID-19: A cohort study of severe patients requiring high flow oxygen therapy or non-invasive ventilation.
De Pascale G; Cutuli SL; Carelli S; Xhemalaj R; Rosà T; Bello G; Vargas J; Cesarano M; Montini L; Tanzarella ES; Pintaudi G; Di Muro M; Grieco DL; Antonelli M
PLoS One; 2022; 17(4):e0267038. PubMed ID: 35482703
[TBL] [Abstract][Full Text] [Related]
13. Real-life use of remdesivir in hospitalized patients with COVID-19.
Garcia-Vidal C; Meira F; Cózar-Llistó A; Dueñas G; Puerta-Alcalde P; Garcia-Pouton N; Chumbita M; Cardozo C; Hernandez-Meneses M; Alonso-Navarro R; Rico V; Agüero D; Bodro M; Morata L; Jordan C; Lopera C; Ambrosioni J; Segui F; Grafia N; Castro P; García F; Mensa J; Martínez JA; Sanjuan G; Soriano A;
Rev Esp Quimioter; 2021 Apr; 34(2):136-140. PubMed ID: 33675220
[TBL] [Abstract][Full Text] [Related]
14. Changing patterns and clinical outcomes of hospitalized patients with COVID-19 severe pneumonia treated with remdesivir according to vaccination status: results from a real-world retrospective study.
Mengato D; Mazzitelli M; Francavilla A; Bettio M; Sasset L; Presa N; Pivato L; Lo Menzo S; Trevenzoli M; Venturini F; Gregori D; Cattelan AM
Clin Exp Med; 2023 Oct; 23(6):2749-2756. PubMed ID: 36961678
[TBL] [Abstract][Full Text] [Related]
15. Patients with moderate to severe COVID-19 outcomes on remdesivir according to baseline 4C mortality score.
Sellers J; Chang J; Jones J; Hintze TD
Pulm Pharmacol Ther; 2023 Feb; 78():102188. PubMed ID: 36603741
[TBL] [Abstract][Full Text] [Related]
16. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
Spinner CD; Gottlieb RL; Criner GJ; Arribas López JR; Cattelan AM; Soriano Viladomiu A; Ogbuagu O; Malhotra P; Mullane KM; Castagna A; Chai LYA; Roestenberg M; Tsang OTY; Bernasconi E; Le Turnier P; Chang SC; SenGupta D; Hyland RH; Osinusi AO; Cao H; Blair C; Wang H; Gaggar A; Brainard DM; McPhail MJ; Bhagani S; Ahn MY; Sanyal AJ; Huhn G; Marty FM;
JAMA; 2020 Sep; 324(11):1048-1057. PubMed ID: 32821939
[TBL] [Abstract][Full Text] [Related]
17. Dexamethasone, dexamethasone + remdesivir in treating moderate to severe COVID-19: retrospective observational cohort study.
Sattoju N; Gattu S; Merugu SS; Anneboina V; Ganapaka SR
J Infect Dev Ctries; 2023 Jul; 17(7):953-960. PubMed ID: 37515802
[TBL] [Abstract][Full Text] [Related]
18. Treatment patterns in US patients hospitalized with COVID-19 and pulmonary involvement.
Best JH; Kong AM; Kaplan-Lewis E; Brawley OW; Baden R; Zazzali JL; Miller KS; Loveless J; Jariwala-Parikh K; Mohan SV
J Med Virol; 2021 Sep; 93(9):5367-5375. PubMed ID: 33913536
[TBL] [Abstract][Full Text] [Related]
19. Early Use of Remdesivir and Risk of Disease Progression in Hospitalized Patients With Mild to Moderate COVID-19.
Falcone M; Suardi LR; Tiseo G; Barbieri C; Giusti L; Galfo V; Forniti A; Caroselli C; Della Sala L; Tempini S; Okoye C; Monzani F; Menichetti F
Clin Ther; 2022 Mar; 44(3):364-373. PubMed ID: 35120742
[TBL] [Abstract][Full Text] [Related]
20. Optimal Timing of Remdesivir Initiation in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Administered With Dexamethasone.
Wong CKH; Lau KTK; Au ICH; Xiong X; Chung MSH; Lau EHY; Cowling BJ
Clin Infect Dis; 2022 Aug; 75(1):e499-e508. PubMed ID: 34420051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
